Natixis Advisors LLC Has $1.99 Million Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)

Natixis Advisors LLC cut its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 20.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,595 shares of the biopharmaceutical company’s stock after selling 9,846 shares during the quarter. Natixis Advisors LLC’s holdings in Cytokinetics were worth $1,985,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Louisiana State Employees Retirement System grew its holdings in shares of Cytokinetics by 0.6% during the third quarter. Louisiana State Employees Retirement System now owns 32,600 shares of the biopharmaceutical company’s stock valued at $1,721,000 after buying an additional 200 shares during the last quarter. UMB Bank n.a. increased its holdings in Cytokinetics by 65.6% during the 3rd quarter. UMB Bank n.a. now owns 601 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 238 shares in the last quarter. First Bank & Trust raised its stake in shares of Cytokinetics by 4.7% in the second quarter. First Bank & Trust now owns 6,757 shares of the biopharmaceutical company’s stock worth $366,000 after purchasing an additional 303 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Cytokinetics by 2.9% in the third quarter. Nisa Investment Advisors LLC now owns 15,062 shares of the biopharmaceutical company’s stock valued at $795,000 after purchasing an additional 430 shares in the last quarter. Finally, J.Safra Asset Management Corp boosted its position in shares of Cytokinetics by 642.3% during the second quarter. J.Safra Asset Management Corp now owns 527 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 456 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on CYTK shares. Needham & Company LLC reissued a “buy” rating and issued a $72.00 price target on shares of Cytokinetics in a research report on Wednesday, November 20th. Royal Bank of Canada began coverage on shares of Cytokinetics in a research report on Friday, November 8th. They set an “outperform” rating and a $80.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 price objective on shares of Cytokinetics in a research report on Monday, November 18th. JPMorgan Chase & Co. lifted their target price on shares of Cytokinetics from $65.00 to $71.00 and gave the stock an “overweight” rating in a research report on Thursday, September 5th. Finally, The Goldman Sachs Group lowered Cytokinetics from a “buy” rating to a “neutral” rating and reduced their target price for the company from $85.00 to $60.00 in a report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, Cytokinetics currently has an average rating of “Moderate Buy” and an average target price of $83.93.

Insider Buying and Selling

In other news, EVP Fady Ibraham Malik sold 6,342 shares of the firm’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $58.48, for a total transaction of $370,880.16. Following the sale, the executive vice president now owns 113,878 shares in the company, valued at approximately $6,659,585.44. This trade represents a 5.28 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Robert I. Blum sold 5,000 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $50.55, for a total transaction of $252,750.00. Following the completion of the transaction, the chief executive officer now owns 397,456 shares of the company’s stock, valued at $20,091,400.80. This trade represents a 1.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 65,078 shares of company stock worth $3,514,119 over the last ninety days. 3.40% of the stock is owned by corporate insiders.

Cytokinetics Stock Performance

Shares of CYTK opened at $50.25 on Tuesday. The stock’s 50-day simple moving average is $53.47 and its 200 day simple moving average is $54.57. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. Cytokinetics, Incorporated has a 52-week low of $30.68 and a 52-week high of $110.25. The stock has a market capitalization of $5.93 billion, a price-to-earnings ratio of -9.34 and a beta of 0.78.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.09). The business had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $1.21 million. Cytokinetics’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same period last year, the firm posted ($1.35) earnings per share. Research analysts forecast that Cytokinetics, Incorporated will post -5.25 EPS for the current fiscal year.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.